sf1126
Small moleculeexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00907205)
Timeline
Indications
Mechanism of action
- Serine/threonine-protein kinase mTORINHIBITOR
MTOR inhibitor
Prodrug - active metabolite is LY-294002. Dual MTOR/PI3K inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor.
- PI3-kinase class IINHIBITOR
PI3-kinase class I inhibitor
Prodrug - active metabolite is LY-294002. Dual MTOR/PI3K inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor.
- Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PIK3CB) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) ↗
- Phosphatidylinositol 3-kinase regulatory subunit beta (PIK3R2) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD) ↗
- Phosphoinositide 3-kinase regulatory subunit 5 (PIK3R5) ↗
- Phosphatidylinositol 3-kinase regulatory subunit gamma (PIK3R3) ↗
- PI3-kinase p85-alpha subunit
- PI3-kinase p110-delta subunit
- PI3-kinase p110-alpha subunit
- PI3-kinase p110-gamma subunit
- PI3-kinase p110-beta subunit
- PI3-kinase p85-beta subunit
- PI3-kinase p110-delta/p85-alpha
- PI3-kinase p110-alpha/p85-alpha
- PI3K p110 beta/p85 alpha
- PI3-kinase subunit gamma/Phosphoinositide 3-kinase regulatory subunit 5
- Phosphatidylinositol 3-kinase regulatory subunit beta/Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform/gamma isoform
- PIK3CG/PIK3R1
- Phosphatidylinositol 3-kinase regulatory subunit gamma
Chemistry & pharmacology
Loading structure…
SMILES
N=C(N)NCCC[C@H](NC(=O)CCC(=O)OC[N+]1(c2cc(=O)c3cccc(-c4ccccc4)c3o2)CCOCC1)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)[O-]- Mol. weight
- 852.86 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL2326966 ↗
Also known as
- sf1126
- sf1126
- sf1126
- sf1126
- sf 1126
- sf-1126
- sf-1126
- sf-1126
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03059147 | Phase 1 | Mar 27, 2017 | Food and Drug Administration, SignalRX Pharmaceuticals, Inc., University of California, San Diego |
| NCT02644122 | Phase 2 | Nov 1, 2016 | SignalRX Pharmaceuticals, Inc., University of California, San Diego |
| NCT02337309 | Phase 1 | Jul 1, 2015 | Harvard University, National Cancer Institute (NCI), SignalRX Pharmaceuticals, Inc., University of Southern California |
| NCT00907205 | Phase 1 | Apr 1, 2007 | Semafore Pharmaceuticals, SignalRX Pharmaceuticals, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SignalRX Pharmaceuticals, Inc. | For profit | 4 | 1 | 2 | 2007 |
| University of California, San Diego | Academic/Hospital | 2 | 1 | 2 | 2016 |
| Food and Drug Administration | Government | 1 | 0 | 1 | 2017 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2015 |
| Semafore Pharmaceuticals | For profit | 1 | 1 | 1 | 2007 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2015 |
7 organizations
Page 1 / 1